Contents
Section 1: General
1. Impact of Higher Prevalence in Countries with Evolving Healthcare Systems and High Multidrug-resistant Tuberculosis Burden
2. How Multidrug-resistant Tuberculosis Poses a Major Challenge to Global TB Control Efforts?
3. Hotspots of Drug-resistant Tuberculosis as Key Drivers of Epidemic Intelligence for Public Health Action
4. Antibiotic Resistance Factors in Multidrug-resistant Tuberculosis
5. Trends in Multidrug-resistant Tuberculosis
6. Barriers in the Development of Specific Drug Susceptibility Testing
Section 2: Diagnostic
7. Decoding Resistance: Role of Mutations in Tuberculosis Treatment Failure
8. Early Detection Tools of Pulmonary Tuberculosis Affecting Treatment Outcome
9. How One Can Lead to Extensively Drug-resistant Tuberculosis?
10. Strain Typing Methods in the Identification of Drug Resistance in Mycobacterium Tuberculosis
11. Pattern and Characteristics of Mutation in Drug-resistant Clinical Isolates of Extrapulmonary Tuberculosis
12. Impact of Genome Sequencing on Multidrug-resistant Tuberculosis Diagnosis and Prevalence
13. Current Advances and Persistent Challenges in the Treatment of Pediatric Drug-resistant Tuberculosis
Section 3: Clinical
14. Closing the Gap between Evidence and Implementation in Multidrug-resistant Tuberculosis Management
15. Significance of Inappropriate or Interrupted Treatment in Tuberculosis
16. Nonadherence to Medication Regimens: Impact on Drug Resistance
17. Strategies to Prevent Mortality and Severe Illness in Multidrug-resistant Tuberculosis
18. Therapeutic Drugs Monitoring in Multidrug-resistant Treatment
Section 4: Treatment
19. Phytochemicals to Combat Multidrug-resistant Tuberculosis
20. Revolutionizing Drug-resistant Tuberculosis Care: The Global BPaL Implementation Experience
21. Poor Drug Quality: Impact on Drug Resistance
22. Surgical Modalities in Multidrug-resistant/Extensively Drug-resistant Tuberculosis
23. Recent Advances in Management of Drug-resistant Tuberculosis
24. Global Drug Pipeline for Tuberculosis Treatment
25. Current Regimens for Drug-resistant Tuberculosis
26. Challenges in Early Detection, Management and Prevention of Multidrug-resistant Tuberculosis in Geriatric Patients
Section 5: Associated Diseases
27. Multidrug-resistant Tuberculosis during Pregnancy
28. Molecular Changes in Diabetes and Multidrug-resistant Tuberculosis
29. Psychiatric Disorders in Drug-resistant Tuberculosis
30. Antimicrobial Resistance Fight: Preventing Drug Resistance
31. Mitigating Strategies to Prevent Drug Resistance
32. Airborne Transmission of Drug-resistant Tuberculosis
33. Problematic Issues in Implementation of Drug-resistant Tuberculosis Case Management
Section 6: Prevention
34. Multidrug Resistance in Tuberculosis: Contact Tracing and Isolation of Infected Individuals
35. Multidrug-resistant Tuberculosis: Infection Prevention and Control Measures in Healthcare Settings
36. Importance of Prevention, Early Diagnosis and Adherence to Treatment: Latent and Subclinical TB
37. Novel Tuberculosis Vaccines: A Promising Approach for Multidrug-resistant Tuberculosis Elimination
Section 7: Newer Initiatives
38. Role of Artificial Intelligence in Tuberculosis
39. Artificial Intelligence in Managing Drug Adherence
40. Role of DNA Fingerprinting in Multidrug-resistant Tuberculosis
41. Epigenetic Regulation of Drug Resistance in Tuberculosis
42. Functional Analysis of Toxin-antitoxin System in Multidrug-resistant Tuberculosis
43. Phenotypic Drug Resistance: An Update in Pediatric Tuberculosis
